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Abstract
 
The mechanisms linking human immunodeficiency virus replication to the progressive immu-
nodeficiency of acquired immune deficiency syndrome are controversial, particularly the relative
contribution of CD4
 
  
 
T cell destruction. Here, we used the simian immunodeficiency virus
(SIV) model to investigate the relationship between systemic CD4
 
  
 
T cell dynamics and rapid
disease progression. Of 18 rhesus macaques (RMs) infected with CCR5-tropic SIVmac239
(
 
n 
 
  
 
14) or CXCR4-tropic SIVmac155T3 (
 
n 
 
  
 
4), 4 of the former group manifested end-stage
SIV disease by 200 d after infection. In SIVmac155T3 infections, naive CD4
 
  
 
T cells were dra-
matically depleted, but this population was spared by SIVmac239, even in rapid progressors. In
contrast, all SIVmac239-infected RMs demonstrated substantial systemic depletion of CD4
 
 
 
memory T cells by day 28 after infection. Surprisingly, the extent of CD4
 
  
 
memory T cell de-
pletion was not, by itself, a strong predictor of rapid progression. However, in all RMs destined
for stable infection, this depletion was countered by a striking increase in production of short-
lived CD4
 
  
 
memory T cells, many of which rapidly migrated to tissue. In all rapid progressors
(P 
 
  
 
0.0001), production of these cells initiated but failed by day 42 of infection, and tissue de-
livery of new CD4
 
  
 
memory T cells ceased. Thus, although profound depletion of tissue
CD4
 
  
 
memory T cells appeared to be a prerequisite for early pathogenesis, it was the inability
to respond to this depletion with sustained production of tissue-homing CD4
 
  
 
memory T cells
that best distinguished rapid progressors, suggesting that mechanisms of the CD4
 
  
 
memory T
cell generation play a crucial role in maintaining immune homeostasis in stable SIV infection.
Key words: AIDS • CD4
 
  
 
T lymphocytes • lymphocyte depletion • immunologic memory • 
rhesus macaque
 
Introduction
 
Progressive cellular immunodeficiency clearly underlies the
clinical disease known as AIDS (1, 2), but even after decades
of investigation, the mechanisms by which HIV replication
disables the immune system are poorly understood (3). The
early association of clinical AIDS with CD4
 
  
 
T lymphopenia
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and the subsequent determination that the causative agent of
AIDS, HIV, directly targets CD4
 
  
 
T cells led to the hy-
pothesis that CD4
 
  
 
T cell destruction results in the loss of
critical immune effector and/or regulatory functions, ulti-
mately degrading immunity below the threshold necessary
to keep opportunistic pathogens at bay (1). Although this
original model has been refined in recent years to include (a)
coreceptor targeting of specific CD4
 
  
 
T cell subpopulations,
(b) indirect mechanisms of CD4
 
  
 
T cell killing (e.g., apop-
tosis) related to chronic activation or interactions with viral
products, and (c) a more dynamic view of the process in
which direct or indirect CD4
 
  
 
T cell destruction is coun-
tered by regenerative mechanisms (3–9), the mechanisms
responsible for this depletion, its precise dynamic nature, its
impact on host immunity, and its relationship to overt im-
mune deficiency have not yet been well characterized.
Simian immunodeficiency virus (SIV) infection of rhesus
macaques (RMs) provides a useful model to explore the
linkage between viral replication, CD4 T cell depletion,
and disease. Although the tempo of both viral replication
and disease progression in this model is significantly accel-
erated compared with human HIV infection, both the
pathobiologic characteristics of SIV (SIVmac and SIVsm
derivatives) and the clinical syndrome associated with its
infection are highly analogous to HIV and human AIDS (6,
10–16). This model allows use of cloned viruses of defined
characteristics, study of the entire course of infection, as
well as repeated access to tissue compartments, and thus
provides for the longitudinal, systemic analysis of a primate
immune system transitioning from normality to clinically
overt insufficiency as a result of infection with an AIDS-
causing lentivirus. Here, we have used this model to inves-
tigate the impact of CCR5- and CXCR4-tropic SIV in-
fection on the composition and dynamics of the CD4
 
 
 
 T
cell compartment, and to determine which, if any, of these
parameters are associated with the development of early
pathogenesis (overt AIDS within 200 d of infection). Our
data strongly associate the early onset of symptomatic dis-
ease with the following two factors: (a) an initial profound
depletion of preexistent CD4
 
  
 
memory T cells in effector
sites, and (b) in those animals with such depletion, a subse-
quent inability to maintain production and tissue delivery
of short-lived CD4
 
  
 
memory T cells. These results specifi-
cally link CD4
 
  
 
memory T cell depletion in tissue with im-
munodeficiency, and provide the first direct evidence that
the sustained increase in CD4
 
  
 
memory T cell proliferation
and turnover associated with lentiviral infection (a compo-
nent of infection-associated chronic “hyperactivation”)
may contribute to survival, allowing RMs to partially com-
pensate for acute CD4
 
  
 
memory T cell loss.
 
Materials and Methods
 
Animals and Veterinary Procedures.
 
34 purpose-bred male RMs
(
 
Macaca mulatta
 
) of Indian genetic background and free of Cerco-
pithicine herpesvirus 1, D-type simian retrovirus, simian T lym-
photrophic virus type 1, and SIV infection were used in this
study. 14 were infected with WT SIVmac239, 4 with SIVmac239
(
 
 
 
nef
 
), 4 with SIVmac155T3, 6 with rhesus CMV (RhCMV)
strain 68.1, and 6 were studied as uninfected controls. SIV infec-
tions were initiated with intravenous injection of 5-ng equiva-
lents of SIV p27 (2.7–3.0 
 
  
 
10
 
4 
 
infectious centers). RhCMV in-
fections were initiated with subcutaneous injection of 10
 
6 
 
PFU.
Bronchoalveolar lavage was performed by infusion and aspiration
of 10-ml aliquots of sterile, pyrogen-free saline using a 3-mm
pediatric fiberoptic endoscope (Olympus) gently wedged into a
subsidiary bronchus. For in vivo 5-bromo-2
 
 
 
-deoxyuridine
(BrdU) pulse labeling, 10 mg/ml of filter-sterilized BrdU, pH 7.2
(Sigma-Aldrich), was prepared in HBSS (Ca
 
2
 
 
 
/Mg
 
  
 
-free; Fisher
Scientific) and administered intravenously at 30 mg/kg body weight
at 24-h intervals for 4 d. All RMs were housed at the Oregon
National Primate Research Center in accordance with the stan-
dards of the Center’s Animal Care and Use Committee and the
“NIH Guide for the Care and Use of Laboratory Animals” (17).
RMs that developed disease states that were not reasonably clini-
cally manageable were killed in accordance with the recommen-
dations of the Panel on Euthanasia of the American Veterinary
Medical Association (18).
 
Viruses and Viral Quantification.
 
The WT SIVmac239 (
 
nef
 
open), SIVmac239(
 
 
 
nef
 
), and SIVmac155T3 clonal virus stocks
were prepared from pBR-SIVmac239, pBR-SIVmac239 
 
 
 
nef
 
,
and pBR-SIVmac155T3 plasmids, respectively. The full-length
pBR-SIVmac239 plasmid was provided by S. Wong (Oregon
Health & Science University, Beaverton, OR; reference 19). The
sequence of pBR-SIVmac239 
 
 
 
nef
 
 (20) was modified to contain
an Mlu1 site at position 9503 that spans the 181-bp 
 
nef
 
 deletion
and results in a frame shift of downstream 
 
nef
 
-coding elements (in-
suring stable 
 
nef
 
 inactivation). The pBR-SIVmac155T3 
 
env
 
 re-
combinant was derived by replacing the 
 
env
 
 sequence in pBR-
SIVmac239 from the Sph1 (nucleotide 6450) to Cla1 (nucleotide
8073) sites with the PCR-derived SIVmac155T3 sequence (21).
The SIVmac155T3 recombinant clone has 22 amino acid differ-
ences compared with SIVmac239 
 
env
 
, and is a novel T cell–tropic
SIVmac variant that uses CXCR4 as the primary coreceptor for
virus entry (CCR5 use is reduced by 10-fold; unpublished data).
Plasmid DNAs were transfected into COS1 cells using TransIT-
LT1 (Mirus Corp.). The culture medium was collected from the
cells 72 h after transfection, sterile filtered, and frozen in aliquots
in liquid nitrogen. The virus stocks were assayed for p27-gag con-
centration by SIV core antigen assay (Beckman Coulter) and for
infectious particles by sMAGI assay (22). Plasma SIV RNA was as-
sessed using a real-time RT-PCR assay, essentially as described
previously (threshold sensitivity 
 
  
 
100 SIV gag RNA copy equiv-
alents/ml of plasma; interassay CV 
 
 
 
25%; reference 23). RhCMV
strain 68.1 was obtained from the American Type Culture Collec-
tion and propagated and titered in RM fibroblasts (24).
 
Immunofluorescent Staining and Flow Cytometric Analysis.
 
PBMCs,
peripheral lymph node cells, and bronchoalveolar lymphocytes
(BALs) were obtained and stained for flow cytometric analysis as
described previously (25). Six-parameter flow cytometric analysis
was performed on a two-laser FACSCalibur instrument using
FITC, PE, peridinin chlorophyll protein-Cy5.5 (True Red),
and allophycocyanin (APC) as the four fluorescent parameters.
List mode multiparameter data files were analyzed using the
PAINT-A-GATE Plus software program (BD Biosciences). Each
analysis included a lineage-defining marker, CD4 or CD8
 
  
 
(with
or without CD3
 
 
 
), and two to three phenotyping markers.
Memory and naive T cell subsets in peripheral blood and lymph
node were delineated based on CD28 and CD95 expression pat-
terns using previously described criteria (25). The specificity of
staining and criteria for setting positive versus negative markers 
Picker et al.
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for CCR5, Ki-67, and BrdU expression were determined using
isotype-matched negative control mAbs, and in the case of BrdU,
BrdU analysis of study animals before BrdU pulsing.
 
mAbs.
 
mAbs L200 (CD4; True Red and APC conjugated),
SP34 (CD3; FITC, PE, True Red, and APC), CD28.2 (CD28;
FITC, PE, True Red, and APC), B56 (Ki-67; FITC and PE),
B44 (anti-BrdU; FITC), DX2 (CD95; PE and APC), 12G5
(CXCR4; PE), 3A9 (CCR5; PE), and IgG1 and IgG2 isotype-
matched controls were obtained from BD Biosciences. mAb
2ST8.5h7 (CD8
 
 
 
; PE, unconjugated) was obtained from Beck-
man Coulter. Purified 2ST8.5h7 was custom conjugated to True
Red by BD Biosciences.
 
Statistical Analysis.
 
Between-group differences in quantitative
dependent variables (except BrdU) were tested at all time points
(days 0–205 after infection) and during acute (days 0–42) and pla-
teau (days 42–205) phases of infection. BrdU decay rates were
compared for 70 d after the last BrdU pulse. Given the small sam-
ple size and reported simulation results (26), we elected not to use
mixed model ANOVA procedures. Instead, we took the mean of
all time points for each animal within each interval, insuring that
for each animal, a single value was modeled and, therefore, that
data were independently distributed. Given the small and unequal
sample sizes across groups in some tests, we conducted further
sensitivity analyses to evaluate the robustness of our findings by
redoing all tests using the nonparametric Wilcoxin rank sum test.
In all cases but one, the conclusion with respect to statistical sig-
nificance for the 
 
t
 
 test was confirmed by nonparametric testing,
lending substantial confidence to the results. In the one case in
which they were different (see Fig. 4), the difference was modest.
 
Results
 
Clinical and Virologic Characteristics of WT and Variant
SIVmac239 Infection.
 
22 RMs were monitored for 205 d
after IV infection with (a) WT (CCR5-tropic) SIVmac239
(
 
n 
 
  
 
14), (b) the (CXCR4-tropic) SIVmac239 
 
env
 
 re-
combinant SIVmac155T3 (
 
n
 
 
 
  
 
4), or (c) the attenuated
SIVmac239(
 
 
 
nef
 
; 
 
n 
 
  
 
4). 10 of the 14 WT SIVmac239-
infected RMs remained free of SIV-related disease during
the first 200 d of infection, and all 10 of these RMs survived
at least 1 yr after infection. In contrast, the remaining four
WT SIVmac239-inoculated RMs developed progressive
disease requiring euthanasia at days 107–175 after infection.
Necropsy revealed one or more AIDS-defining opportu-
nistic infections in all four of these animals (Table I). Viral
replication in the 14 RMs inoculated with WT SIVmac239
was quite high, with peak viral loads (almost invariably at
day 10 after infection) ranging from 2 
 
  
 
10
 
7 
 
to 2 
 
  
 
10
 
8
 
copies/ml, and plateau phase viral loads from 10
 
5 
 
to 
 
 
 
10
 
8
 
copies/ml (Fig. 1 A). One RM with the protective 
 
Mamu
Figure 1. Plasma viral loads (A) and absolute peripheral
blood CD4  T cell counts (B) in CCR5-tropic, CXCR4-
tropic, and attenuated SIV infections. Data from all 22 SIV-
infected RMs included in this work are shown: 4 each with
SIVmac239( nef) (dark blue traces) and SIVmac155T3 (light
blue), and 14 with WT SIVmac239, of which 4 were rapid
(red) and 10 (black) were normal progressors. Both acute
and plateau phase viral loads were significantly higher in
the rapid progressor RMs than in their clinically stable
SIVmac239-infected counterparts. P   0.004 and 0.001
(t test), and P   0.02 and 0.01 (Wilcoxin rank sum) for on
or before, or after, day 42 after infection, respectively. The
absolute CD4 counts of these two groups were signifi-
cantly different after day 42 after infection (P   0.001 and
0.01 for t and Wilcoxin rank sum tests, respectively), but
paradoxically, although the normal progressors showed the
expected slow decline in CD4 counts, rapid progressors
showed a pronounced CD4  T lymphocytosis. 
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A
 
*
 
O1/B
 
*
 
17 MHC alleles (27) manifested spontaneous,
temporary control of viral replication to 
 
 
 
100 copy 
 
equiva-
lents
 
/ml at day 56 after infection, but reverted to a high
replicative state (viral loads 
 
  
 
4 
 
  
 
10
 
5
 
) 
 
 40 d later. In
keeping with previous studies (16, 28, 29), the plasma viral
loads in the four rapid progressors, particularly the post-
acute phase ( day 42 after infection) viral levels, were sig-
nificantly higher than in the normal progressor group (Fig.
1, legend). However, it is noteworthy that two of that lat-
ter group manifested viral replication kinetics overlapping
that of the rapid progressors, yet maintained immune com-
petence for  1 yr after infection.
The peak viremias observed in the SIVmac239( nef)-
infected RMs, as is characteristic of these infections (30),
was blunted compared with WT SIVmac239, and post-
acute viral loads stabilized in the 2–3 log range (Fig. 1 A).
SIVmac155T3 is a novel variant of SIVmac239 with 22
amino acid substitutions in gp120 that confer dominant
CXCR4 tropism. Peak viral loads with this clone were
similar to those of WT SIVmac239, but plateau phase
viremia was considerably reduced, ranging from 103 to 105
copies/ml (Fig. 1 A). All of the SIVmac239( nef)- and
SIVmac155T3-infected RMs studied here remained healthy
for  1 yr after infection.
SIV Coreceptor Tropism, Patterns of CD4  T Cell Depletion,
and Early Disease Progression. Although total peripheral
blood CD4 counts have long been the benchmark of immu-
nologic assessment of disease progression in both HIV and
Table I. Clinical and Pathologic Features of WT SIVmac239-infected Rapid Progressor RMs
RM no. Clinical findings Pathologic findings at necropsy
20165 Day 95a: Diarrhea, dehydration, electrolyte imbalance Disseminated CMV infection: small intestine, prostate,
epididymis, and leptomeninges
Day 126: Diarrhea, dehydration, electrolyte imbalance,
thrombocytopenia, weight loss (15%),
euthanasia
Cryptosporidiosis: cholecystitis, cholangitis,
and cholangiohepatitis
Mesangioproliferative glomerulonephritis
Lymphoid depletion: lymph nodes, spleen, and thymus
20322 Day 111: Diarrhea, vomiting Lymphocytic interstitial pneumonia
Day 120: Diarrhea, dehydration, anorexia Protozoal (flagellate) gastritis
Day 126: Weight loss (13%), euthanasia Cryptosporidiosis: cholecystitis, cholangitis,
cholangiohepatitis, and enteritis
Ulcerative colitis 
Mesangioproliferative glomerulonephritis
Lymphoid depletion: lymph nodes, spleen, and thymus
20418 Day 125: Diarrhea, dehydration Pneumocystis carinii pneumonia
Day 172: Diarrhea, dehydration, anorexia Disseminated CMV infection: right atrioventricular
valve, spinal cord leptomeninges, nerves, and ganglia
Day 175: Weight loss (14%), euthanasia Diffuse nonsuppurative gastritis
Cryptosporidiosis: cholecystitis, cholangitis,
and cholangiohepatitis
Mesangioproliferative glomerulonephritis
Lymphoid depletion: lymph nodes, spleen, and thymus
21070 Day 56: Thrombocytopenia CMV pneumonia
Day 93: Diarrhea, Campylobacter coli and
flagellate protozoa
Aspiration pneumonia
Granulomatous cholangiohepatitis
Day 104: Diarrhea, dehydration, electrolyte imbalance,
anorexia;
Hemorrhagic, ulcerative bacterial gastritis and enteritis
Lymphoid depletion: lymph nodes, spleen, and thymus
Elevated LDH, SGPT/OT, BUN, creatinine
Day 107: Diarrhea, dehydration, electrolyte imbalance,
anorexia, anemia, weight loss (12%), euthanasia
aDays are all after infection.Picker et al. 1303
SHIV infection (1, 2, 31, 32), this parameter was not predic-
tive of early pathogenesis in the SIV-infected RMs studied
here (Fig. 1 B). Although the healthy SIVmac239( nef)-
infected RMs in this work showed the expected stability
of these counts (indeed, on average, CD4  T cell numbers
rose 39% in these RMs), the clinically indistinguishable
SIVmac155T3-infected cohort showed rapid and profound
initial depletion ( 90%), followed by a delayed, slow re-
bound. Although the postinfection course of total CD4
counts in the clinically stable WT SIVmac239-infected RMs
showed considerable variability, overall, these animals mani-
fested a slow decline in total CD4  T cell counts, averaging
44% over the 200 d of observation. Paradoxically, the WT
SIVmac239-infected RMs destined for early pathogenicity
(rapid progressors) uniformly demonstrated a striking (ap-
proximately threefold) CD4  T lymphocytosis, starting at
about day 42 after infection, and extending until the onset of
overt disease (usually 2–3 wk before they were killed).
CD4  T cells in peripheral blood are a composite of
two phenotypically and functionally distinct subpopula-
tions: the naive and memory/effector subsets (25), each
with a characteristic pattern of coreceptor expression. As
illustrated in Fig. 2, A and B (top), the primary coreceptor
for WT SIVmac239, CCR5, is almost exclusively ex-
pressed by a subset of memory CD4  T cells (mean
CCR5    SD for 21 uninfected RMs   21.8   7.7% of
CD4  memory T cells in peripheral blood). The alterna-
tive coreceptor CXCR4 is robustly expressed by both
subsets, with the intensity of expression highest on na-
ive  cells (Fig. 2 B, top). Infection with CCR5- versus
CXCR4-tropic SIV resulted in dramatically different changes
in CD4  T cell subset composition, in keeping with core-
ceptor-directed targeting. As shown in Fig. 2 A, a typical
CCR5-tropic WT SIVmac239 infection induced a 75%
loss of CD4  memory T cells by day 49 after infection,
and within the memory population, a 75% depletion of
the CCR5-expressing population. Concomitant with this
striking depletion of CCR5-expressing, CD4  memory T
cells, we observed a prominent change in the proliferation
status of this subset, as measured by the cell cycle marker
Ki-67 (25). Whereas before infection, CCR5  CD4 
memory T cells were predominantly Ki-67 , after infec-
tion-associated depletion, this subset was predominantly
Ki-67bright. Thus, circulating CCR5  CD4  memory T
cells are markedly depleted in SIVmac239 infection with
the small, residual CCR5  subset appearing to be main-
tained by a proliferative process. In contrast, a typical
CXCR4-tropic SIVmac155T3 infection profoundly and
preferentially depleted the naive CD4  subset in the same
timeframe (Fig. 2 B). CXCR4-expressing CD4  memory
T cells were not resistant to this virus, but this subset ap-
peared to down-regulate CXCR4 expression so as to es-
cape wholesale depletion. The frequencies of CCR5  cells
within the CD4  memory T cell population actually in-
Figure 2. CD4  T cell depletion patterns in CCR5- (A) versus CXCR4-tropic (B) SIV infection. (A) PBMCs from a typical WT SIVmac239-infected
normal progressor were examined for their correlated expression of cell surface CD4 versus CCR5 versus CD28 versus CD95 or CD4 versus CCR5 versus
Ki-67 versus CD95, both before and 49 d after infection (viral load   7.4   106 copies/ml and absolute blood CD4 counts   500 cells/ l at day 49 after
infection). 5,000 events, gated on total CD4  T cells (left and middle) or CD4  (CD95high) memory T cells (right) are shown. Overall, naive (blue) and
memory (red) T cell frequencies are shown in the upper right corner of the left panels. The percent CCR5  within the memory subset is shown in the
middle panels, and the memory subsets defined by CCR5 versus Ki-67 are shown in the right panels. Note the striking relative depletion of CD4  memory
T cells, and within the memory population, the CCR5-expressing subset, with this subset going from predominantly Ki-67  preinfection to predomi-
nantly Ki-67bright  postinfection (arrows). (B) PBMCs from a representative SIVmac155T3-infected RM were examined for their correlated expression of
cell surface CD4 versus CCR5 versus CD28 versus CD95 or CD4 versus CXCR4 versus CD28 versus CD95, both before and 49 d after infection (viral
load   1.2   105 copies/ml and absolute blood CD4 count   440 cells/ l at day 49 after infection). 5,000 events, gated on total CD4  T cells are shown
with events within the naive and memory cell clusters colored blue and red, respectively. Note the profound loss of naive CD4  T cells, increased fre-
quencies of CCR5  cells among CD4  memory T cells, and loss of CD4  T cell CXCR4 staining intensity, particularly within the memory subset.Determinants of Rapid Progression in SIV Infection 1304
creased in SIVmac155T3-infected RMs due to CCR5 ex-
pression by the proliferating subset (see below).
Analysis of absolute peripheral blood naive and memory
T cell numbers in the different cohorts confirms and ex-
tends these findings (Fig. 3). In SIVmac239( nef)-infected
RMs, absolute numbers of naive and memory CD4  T
cells in blood fluctuated over time, but overall, preinfection
levels of both subsets were maintained for  200 d after in-
fection. In SIVmac155T3 infection, the aforementioned
rapid loss of circulating CD4  T cells can be seen to be pri-
marily the result of naive T cell depletion (essentially com-
plete depletion was also observed in lymph nodes). Circu-
lating CD4  memory T cell numbers declined modestly
during acute infection with this X4-tropic virus, but re-
bounded, and remained stable thereafter. In contrast,
among WT SIVmac239-infected normal progressors, naive
CD4  T cell numbers were stable, whereas memory CD4 
T cell numbers demonstrated an abrupt decline in acute in-
fection (after a brief CD4  memory T lymphocytosis at day
7 after infection), followed by a slow decline thereafter. 4
of the 10 normal progressors showed some fluctuating or
transient rebound in these CD4  memory T cell numbers,
but even for these RMs, the overall trend was downward.
Among the SIVmac239-infected rapid progressors, the
above-described CD4  T lymphocytosis is clearly attribut-
able to the naive subset, which given the low turnover of
this population (25), likely reflects a redistribution of these
cells from tissue to blood. Circulating CD4  memory T
cells uniformly decline in these RMs, but the kinetics and
extent of this loss are largely overlapping with that of the
normal progressors.
Representation of the CCR5-expressing component of
the CD4  memory population briefly increased in blood at
day 7 after infection in all WT SIVmac239-infected RMs,
but then rapidly declined (Fig. 4 A). In the clinically stable
WT SIVmac239-infected RMs, the decline during acute
infection was accompanied, as indicated above, by the ap-
pearance of Ki-67  CCR5  CD4  T cells, which either
maintained this fraction at a low level (at least 5% of the
memory fraction; 5 of 10 RMs), or increased it back toward
normal levels (the other 5 normal progressors). The initial
decline of this population was similar in rapid progressors,
but in contrast to the normal progressors, there was little ev-
idence of rebound, and after day 42 after infection, the fre-
Figure 3. Absolute peripheral
blood CD4  memory (A) and naive
(B) T cell counts in CCR5-tropic,
CXCR4-tropic, and attenuated SIV
infections. Absolute memory (A)
and naive (B) CD4  T cell counts
were determined using absolute total
CD4 counts (see Fig. 1) and naive/
memory fractions based on CD28
versus CD95 staining criteria (refer-
ence 25). Data for all 22 SIV-infected
RMs are shown. Rapid progressors
did not differ from normal progressors
in regard to memory CD4  T cell
numbers (P   0.11 and 0.18 for days
0–200 after infection by t and Wil-
coxin rank sum tests, respectively).
In contrast, with the onset of the
plateau phase of infection, rapid pro-
gressors manifested a pronounced
CD4  naive T cell lymphocytosis,
whereas naive CD4  T cell numbers
in normal progressors were largely
stable (P   0.0001 and P   0.006 for
after day 42 after infection by t and
Wilcoxin rank sum tests, respectively).Picker et al. 1305
quency of CCR5-expressing cells among CD4  memory T
cells was  3%, significantly lower than the normal progres-
sor group (Fig. 4). The CCR5-expressing memory fraction
increased in RMs infected with CXCR4-tropic SIV, and
did not change in attenuated ( nef) SIV infection.
Previous work has established that CCR5 is expressed by
the vast majority of CD4  memory T cells in mucosal tis-
sues such as the intestinal and vaginal mucosae and the tis-
sue–air interface of the lung, and that these populations are
subject to extensive, acute depletion during CCR5-tropic
SIV infection (4, 13, 33–35). Using the latter (BALs) as a
repeatedly accessible “window” into the mucosal tissue
compartment, we determined the relationship between the
rate and extent of “effector” site CD4  T cell depletion and
clinical course in our study cohorts. As shown in Fig. 4 B,
CD4  T cell numbers in BALs were stable during early in-
fection with either attenuated SIVmac239( nef) or CXCR4-
tropic SIVmac155T3 infections, but rapidly declined with
CCR5-tropic WT SIVmac239 infection. Normal progres-
sors lost, on average, 82% of their lung CD4  T cells by
day 21 after infection (range: 63–96%), and 86% by day 28
after infection (range: 71–97%). Thereafter, about half of
these RMs were able to transiently and partially regenerate
CD4  T cell percentages in the lung, whereas in the
others, the CD4  T cell fraction declined to  1%. WT
SIVmac239-infected rapid progressors demonstrated a uni-
form 98–99% decline in CD4  T cell frequencies by day 21
after infection, and showed no significant regeneration.
Statistical assessments of the differences in the extent and
kinetics of CD4  (memory) T cell depletion in BALs in
WT SIVmac239-infected normal versus rapid progressors
were equivocal, with t tests suggesting significance after,
but not before, day 42 after infection and nonparametric
testing indicating the reverse (Fig. 4 B).
CD4  Memory T Cell Regenerative Failure Precedes and Pre-
dicts Rapid Progression. Next, we assessed whether differ-
ences in CD4  memory T cell proliferation and turnover
correlated with clinical outcome, particularly in animals
with substantial acute-phase CD4  memory T cell depletion
in tissue. Two approaches were used to investigate this is-
sue. First, we serially determined the fraction of CD4  (and
for comparison, CD8 ) memory T cells expressing the pro-
liferation marker Ki-67 (Fig. 5). Ki-67 expression provides a
running average of the fraction of cells that have recently
gone through S phase of the cell cycle with moderate/
bright and dim staining reflecting S phase in the 3–4 and
Figure 4. Depletion patterns of CCR5 
CD4  memory T cell “targets” in blood (A)
and tissue (B) in CCR5-tropic, CXCR4-
tropic, and attenuated SIV infections. (A) The
percent of cells expressing CCR5 within the
peripheral blood CD4  memory subset was
determined as shown in Fig. 2. Data on this
parameter  were not available for one WT
SIVmac239-infected, rapid progressor and two
SIVmac239( nef)-infected RMs; all other study
RMs are included in the figure. The difference
in CCR5  CD4  memory T cell frequencies
between rapid and normal progressors was sig-
nificant in plateau phase. P   0.004 and 0.01
for after day 42 after infection by t and Wil-
coxin rank sum tests, respectively. (B) The per-
centage of CD4  cells within the total popula-
tion of CD3  BAL T cells is shown for 18 of
the 22 SIV-infected RMs. In the four RMs not
shown, BAL data was not obtained until day 77
after infection or later. The two of these RMs
infected with SIVmac239( nef) demonstrated
normal CD4  T cell representation in BALs
(33–39%) at these later time points (consistent
with no depletion). In contrast, the two of these
RMs infected with WT SIVmac239, one a
rapid progressor and one a normal progressor,
both demonstrated CD4  T cell frequencies in
BALs of  1% after day 77 after infection (con-
sistent with profound depletion). Statistical
comparison of the degree of depletion in
SIVmac239-infected rapid versus normal pro-
gressors was equivocal. In acute infection (before
day 42 after infection), the difference in CD4 
T cell percentages between WT SIVmac239-
infected rapid and normal progressors was sig-
nificant at P   0.02 by the Wilcoxin rank sum
test, but not by the t test. After day 42 after in-
fection, the reverse was true: the t test demon-
strated a p-value of 0.008, whereas the Wil-
coxin rank sum test was not significant.Determinants of Rapid Progression in SIV Infection 1306
5–8 d before sampling, respectively (25). Second, we la-
beled proliferating cells in vivo at strategic time points after
infection with the thymidine analogue BrdU, followed by
serial measurement of the fraction of CD4  memory cells
retaining this DNA label. Peak BrdU incorporation imme-
diately after the last BrdU dose provides an independent
measurement of the proliferating fraction, and the relative
kinetics of BrdU decay during the wash-out period provides
insight into the relative fate of the proliferating component
over that time period. To facilitate interpretation of BrdU
decay kinetics in SIV-infected RMs, we included two con-
trol groups in the study: healthy uninfected RMs (n   6)
and healthy RMs with primary RhCMV infection (n   6).
These analyses revealed that SIV infection, in general,
results in profound changes in CD4  memory T cell turn-
over. In the first 7–10 d after infection with any of the SIV
variants, coincident with peak viral replication, most ani-
mals showed a transient drop in the fraction of Ki-67  cells
within the circulating CD4  memory T cell population.
However, starting on days 14–21 after infection, the fre-
quency of Ki-67  cells within this population dramatically
increased (Fig. 5). For WT SIVmac239-infected normal
progressors, the fraction of CD4  memory T cells express-
ing Ki-67 on day 42 after infection increased from prein-
fection values by an average ( SEM) of 2.6 ( 0.3)-fold
(an average increase of 27   2.1 percentage points). A sim-
ilar increase in Ki-67 expression was observed in CD4 
memory T cells in lymph nodes (not depicted) and in
CD8  memory T cells (Fig. 5). Most noteworthy, how-
ever, was the observation that the infection-associated in-
crease in CD4  memory T cell proliferation was sustained
in all SIV-infected animals except those destined for rapid
progression. In all four rapid progressors, the CD4  mem-
ory proliferative response initiated with normal kinetics
(peak percent Ki-67 within the CD4  memory subset in
blood during the acute phase, day 14–30 after infection,
was 4.1-   0.9-fold higher than preinfection levels), but
failed by day 42 after infection, with CD4  memory T cell
proliferative frequencies returning back to or toward base-
line levels (Fig. 5). After day 42 after infection, the differ-
ence in CD4  memory T cell proliferative frequencies be-
tween RMs destined for normal versus rapid progression
was highly significant (P   0.0001 by t test). Significantly,
proliferative failure was CD4 memory T cell specific. There
was no difference in the postinfection proliferative kinetics
of CD8  memory T cells between rapid and normal pro-
gressing WT SIVmac239-infected RMs.
Peak BrdU labeling in the acute phase of infection (days
10–13 or 24–27 after infection) confirmed the CD4  mem-
ory T cell proliferative “burst,” with mean   SEM of maxi-
mum percent BrdU  of blood CD4  memory T cells as
5.4     0.5% for uninfected RMs, 20.6    1.7% for WT
SIVmac239-infected normal progressors, 16.2   5.1% for
WT SIVmac239-infected rapid progressors, 21.9   5.3%
for  SIVmac155T3-infected RMs, and 14.7    1.2% for
SIVmac239( nef)-infected RMs (all SIV cohorts were signif-
icantly different from uninfected controls with t test p-values
from 0.02 to  0.001). During the post-BrdU pulse “wash-
out” period, BrdU  memory T cells decline in frequency in
a multiphasic process (25). In the initial 4 d of washout
(phase 1), most BrdU  cells are Ki-67moderate–high, indicating
many are still cycling, and labeled cells decline in frequency
because of proliferative dilution ( 5 postlabel divisions), as
well as loss from the circulating pool (Fig. 6, A and B). From
washout days 4–14 (phase 2), labeled cells have largely left
the cell cycle (manifested by loss of Ki-67 expression and sta-
Figure 5. CD4  and CD8  memory T cell proliferation in CCR5-tropic, CXCR4-tropic, and attenuated SIV infections. PBMCs were examined for
their correlated expression of Ki-67 versus CD28 versus CD95 versus either CD4 or CD8 , and the percent Ki-67  was determined for the memory T
cell subset of each lineage. The figure includes CD4  lineage data from all 22 SIV-infected RMs, and CD8 lineage data for all 14 RMs infected with WT
SIVmac239. The plateau phase differences in CD4  memory T cell proliferation (e.g., percent Ki-67 ) between the SIVmac239-infected normal and
rapid progressors was highly significant with P   0.0001 and P   0.006 for after day 42 after infection by t and Wilcoxin rank sum tests, respectively. In
contrast, CD8  memory T cell proliferation during the same time period did not significantly differ between these two groups.Picker et al. 1307
bilization of BrdU staining intensity), and display a relatively
rapid removal from the recirculating pool, as compared with
the considerably slower, steady loss at later time points (phase
3). In SIV-infected RMs, loss of labeled cells in phases 1 and
2 was dramatically increased versus uninfected RMs (80 to
 90% vs.  50%), consistent with a great predominance of
high turnover/short-lived cells within the CD4  memory
proliferative burst. This CD4  memory BrdU decay pattern
was observed in acute SIV infection of all types, as well as
primary RhCMV infection (Fig. 6 C), suggesting it is a
common response to viral infection. Importantly, there was
no significant difference between the CD4  memory BrdU
decay kinetics of the WT SIVmac239-infected RMs des-
tined for normal versus rapid progression, or between either
of these groups and the SIVmac155T3-infected RMs. Thus,
the rate and extent to which proliferating CD4  memory T
Figure 6. BrdU decay kinetics in circulating CD4  memory T cells in normal RMs, primary RhCMV infections, and CCR5-tropic, CXCR4-tropic,
and attenuated SIV infections. SIV-infected and control RMs (either uninfected or 1  RhCMV infected) were administered 30 mg/kg BrdU IV for 4
consecutive days, with the first sampling occurring 24 h after the last BrdU dose. In the SIV infections, acute phase labeling was performed either on days
10–13 after infection or days 24–27 after infection. Plateau phase labeling was performed after day 99 after infection. In the 1  RhCMV infections, label-
ing was performed on days 10–13 after infection. (A and B) The correlated expression of BrdU versus Ki-67 on CD4  CD95high (memory) T cells from
representative healthy, uninfected (A) and WT SIVmac239-infected normal progressor (B) RMs are shown (each profile with 5,000 gated events). The
percentages in the upper right corners of the profiles represent the total BrdU  fraction of the gated CD4  memory cells. The dotted horizontal lines
delineate the upper extent of the negative population in the Ki-67 channel and serve as a reference for evaluating the progressive loss of Ki-67 expression
by BrdU  cells. (C) PBMCs were stained for BrdU versus CD28 versus CD95 versus CD4 at the designated time points, and percent BrdU  was deter-
mined for the CD4  memory subset. The decay kinetics of BrdU  (CD4  memory) cells in all acutely infected cohorts were significantly different from
uninfected animals (P   0.0001 by t test for normal vs. 1  RhCMV-, WT SIVmac239-, SIVmac155T3-, or SIVmac239( nef)-infected RMs), but these
kinetics did not significantly differ between WT SIVmac239-infected rapid versus normal progressors (P   0.84 by t test), or between either of these
cohorts and RMs infected with SIVmac155T3 (P   0.15 and 0.06, respectively).Determinants of Rapid Progression in SIV Infection 1308
cells are lost from the recirculating pool in acute SIV infec-
tion does not correlate with rapid progression.
As mentioned above, Ki-67 frequencies in the CD4 
memory population of WT SIVmac239-infected normal
progressors remain high throughout the period of observa-
tion (Fig. 5), and plateau phase (after day 100 after infec-
tion) BrdU analysis of this population (Fig. 6 C, far right)
demonstrates continued rapid decay, suggesting that the
high turnover state is similarly maintained. Significantly, in
the one WT SIVmac239-infected rapid progressor that sur-
vived long enough for a plateau phase BrdU decay analysis
(i.e., after the onset of proliferative failure), CD4  memory
T cell BrdU decay kinetics was similar to that of uninfected
RMs, suggesting that collapse of the infection-associated
proliferative burst abrogates the high turnover/short-lived
component of CD4  memory proliferation, leaving a low
turnover/long-lived component behind.
Delivery of CD4  Memory T Cells to the Pulmonary Mu-
cosal Surface in Stable versus Rapidly Progressive Infection. The
potential impact of CD4  memory T cell proliferative fail-
ure on CD4  memory populations in effector sites, and its
possible link with rapid disease progression, was first re-
vealed by comparison of BrdU versus Ki-67 staining pat-
terns and BrdU kinetics in the blood, lymph node, and
lung of (plateau phase) WT SIVmac239-infected normal
progressors. As shown in Fig. 7 A, 24 h after the last dose of
a 4-d BrdU pulse, the vast majority of BrdU-labeled CD4 
memory T cells in the blood and lymph node are also Ki-
67 , indicating that they are relatively close to their last S
phase. In contrast, at the exact same time, BrdU-labeled
CD4  memory T cells in the lung are predominantly Ki-
67  or dim, strongly suggesting that these cells are more re-
mote from their most recent S phase, and did not go
through S phase in the lung itself. This impression is
strengthened by the observation that although maximum
BrdU labeling in the blood and lymph node occurs 24 h af-
ter the last BrdU dose, maximum BrdU labeling in the
lung occurs 7 d later (Fig. 7 C). These data lead to the con-
clusion that the pulmonary mucosal surface in these RMs is
continually supplied by an influx of new CD4  memory T
cells that are the products of prior proliferative events oc-
curring elsewhere.
Thus, the postinfection CD4  memory proliferative re-
sponse appears to provide a steady influx of new CD4 
memory T cells in mucosal effector sites, potentially coun-
tering the severe CD4  T cell depletion in these sites and
preventing overt immunodeficiency. Although accurate di-
rect measurement of BrdU-labeled CD4  T cell influx into
the lungs was not possible in severely depleted SIV-infected
animals, the phenotypic signatures of lung CD4  T cells in
normal versus rapid progressors strongly support this hy-
pothesis. As shown in Fig. 7 B, newly produced, BrdU-
labeled memory CD4  T cells in the blood and lymph node
might be either CCR5  or CCR5 , but those arriving in
Figure 7. BrdU labeling and decay kinetics in the blood versus lymph node versus lung in a plateau phase WT SIVmac239-infected normal progressor.
(A and B) 1 d after BrdU administration on days 99–102 after infection, PBMCs, lymph node cells, and BALs from a clinically stable WT SIV mac239-
infected RM were examined for correlated expression of CD4, BrdU, and either Ki-67 (A) or CCR5 (B), with CD95 also used in PBMC and lymph
node analyses to delineate the CD4  memory subset. 5,000 events are shown, gated on CD4  CD95high memory T cells in PBMC and lymph node prep-
arations, and on total CD4  T cells (which are all memory) in BALs. In A, the percentages of BrdU  cells within these gated populations are shown in
the upper right hand corner of each profile, with the percentages adjacent to the arrows indicating the fraction of these BrdU  cells that are also Ki-67 .
In B, the percentages adjacent to the arrows indicate the fraction of BrdU  cells that are also CCR5 . (C) The percent of CD4  memory T cells demon-
strating BrdU reactivity are plotted for each site over the time course shown. The results shown are representative of three plateau phase SIVmac239-infected
normal progressors and four SIVmac155T3-infected RMs.Picker et al. 1309
the lung are almost all CCR5 . Moreover, although BrdU 
cells arriving in lung have undergone S phase elsewhere,
many of them retain low level Ki-67 reactivity (Fig. 7 A).
Taken together, these observations suggest that most new
emigrants to lung will express Ki-67, CCR5, or both mark-
ers. As illustrated in Fig. 8 A, BAL CD4  T cells of all WT
SIVmac239-infected normal progressors did indeed pre-
dominantly express either or both CCR5 and Ki-67 at all
plateau phase time points (mean   SEM for BAL CD4  T
cells lacking both Ki-67 and CCR5   12.1   4.5%), nota-
bly including those RMs with profound CD4  T cell de-
pletion in the lung (e.g.,  1% CD4  T cells). In striking
contrast (Fig. 8 B), the residual BAL CD4  T cells of the
rapid progressors were almost entirely negative for both
CCR5 and Ki-67 (mean   SEM for BAL CD4  T cells
lacking both Ki-67 and CCR5   84.6   2.4%). These dif-
Figure 8. Pulmonary CD4 
T cell phenotype in WT
SIVmac239-infected rapid versus
normal progressors. BAL prepa-
rations were examined for corre-
lated expression of CD4, CD8 ,
Ki-67, and CCR5 at different
plateau phase time points in all
14 WT SIVmac239-infected
RMs. The profiles are gated on
CD4  T cells with all available
events shown ( 200). The per-
cent of CD4  T cells (of total T
cells) in each BAL specimen is
indicated in the upper left of
each profile. The quadrant statistics
for CCR5 versus Ki-67 expression
are provided in the upper right
of each profile. The plasma viral
loads (p.v.l.   106 copies/ml) for
each time point represented are
shown beneath each profile.
The profiles of WT SIVmac239-
infected  normal progressors are
representative of the patterns ob-
served during plateau phase in all
10 RMs in this cohort with the
salient, common feature being
that the majority of lung CD4 
T cells in these RMs expressed
either CCR5, Ki-67, or both. In
contrast, in all rapid progressors,
 80% of residual CD4  T cells
in the BALs of rapid progressors
lacked both CCR5 and Ki-67
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ferences were highly significant (P    0.0001 by t test).
Thus, even though normal and rapid progressors may have
had identical overall frequencies of lung CD4  T cells, the
phenotypes of these T cells strongly suggest that the lungs of
the clinically stable RMs were receiving a continuous influx
of newly produced CD4  effector T cells, whereas the lungs
of animals destined for rapid progression were not.
Discussion
In the setting of RM infection with pathogenic CCR5-
tropic SIV, there is little question that viral replication
drives pathogenesis (16, 28, 29), and that the origin of rapid
progression clearly lies in the relatively high levels of viral
replication during early infection, most likely resulting
from (a) intrinsic host differences in cellular susceptibility to
productive infection with the virus in question (28, 36), (b)
host immune factors (37, 38), and/or (c) concomitant in-
fection (39, 40). However, some CCR5-tropic SIV-infected
RMs can maintain immune homeostasis for long periods
despite viral loads as high as, or nearly as high as, rapid pro-
gressors (Fig. 1 A), suggesting that high viral replication
produces disease (e.g., overt immune deficiency) through
differentially regulated host mechanisms. Here, we sought
to critically examine the role of CD4  T cell depletion in
this “downstream” pathogenetic sequence by analyzing in
detail the dynamics of this population in rapidly progres-
sive, normally progressive, and non- or slowly progressive
SIV infection, as well as a control non-SIV infection, and
then determining which, if any, of the dynamic parameters
are common to viral infection in general or to SIV infec-
tion alone, and of the latter, which are closely linked to
early pathogenesis.
The first significant observation is that total CD4  T cell
depletion is not required for acute pathogenesis, an obser-
vation in agreement with other reports demonstrating rapid
progression in the absence of severe CD4  T cell depletion
in blood and lymphoid tissues (41–43). The more detailed
analyses of this work unambiguously demonstrate that fun-
damental differences in coreceptor-mediated SIV targeting
of the major peripheral CD4  T cell subpopulations, naive
versus memory, underlie this seemingly incongruous obser-
vation. CD4  T cell expression of the CCR5 coreceptor is
largely restricted to memory T cells, including a relatively
small subset in blood and secondary lymphoid tissues, but
the vast majority of such cells in tissue effector sites (intesti-
nal lamina propria, vaginal mucosa, lung, liver, skin, and
synovium; reference 44). CCR5-tropic SIV selectively de-
pletes this population (this paper and references 13, 33, and
35), and all rapid progressors manifested profound memory
depletion before the onset of overt disease. In contrast, na-
ive CD4  T cells, which lack CCR5 expression, appear to
escape destruction in acute/early CCR5-tropic SIV infec-
tion, even with the high viral replication of rapid progres-
sors. Naive cells account for the paradoxical CD4  T lym-
phocytosis associated with rapid progression, and comprise
the vast preponderance of the “preserved” CD4  T cell
compartment (41) in the lymphoid tissues of rapid progres-
sors found at necropsy (not depicted). Moreover, naive
CD4  T cells are selectively depleted in (CXCR4-tropic)
SIVmac155T3-infected RM; yet, these animals remain
healthy as long as memory T cell numbers are maintained
(particularly in tissues).
Taken together, these observations implicate the CD4 
memory T cell compartment as a primary participant in
SIV pathogenesis. However, when we explicitly asked
whether faster and/or greater depletion predicted the ac-
celerated disease course in rapid progressors, we found,
somewhat surprisingly, that the rate and extent of CD4 
memory T cell depletion in rapid progressors either over-
lapped with (total memory T cells in blood) or was only
very marginally greater/faster than (CCR5  CD4  mem-
ory T cells in blood and lung) the lower end of the normal
progressor spectrum for the same parameters. Thus, even
the relatively reduced viral replication level characteristic of
normal progression is frequently sufficient to massively de-
plete CD4  memory T cells in tissue, suggesting that al-
though such depletion may ultimately be required for overt
immunodeficiency, it is not, by itself, sufficient to trigger
its onset. However, one intriguing difference between the
CD4  memory depletion patterns of WT SIVmac239 nor-
mal and rapid progressors was observed: the latter cohort
showed little or no rebound in CD4  memory T cell pop-
ulations after approximately day 42 after infection, suggest-
ing that this subset’s regenerative potential might be com-
promised in the rapid progressors.
Direct analysis of CD4  memory T cell dynamics sup-
ported this hypothesis. As has been previously reported
(45–49), SIV infection is associated with a striking increase
in CD4  memory T cell proliferation (as measured by both
Ki-67 expression and in vivo BrdU uptake) and turn-
over (as measured by BrdU decay), starting  2–3 wk after
infection. This increased memory proliferation and turn-
over occurred in the absence of overt depletion (e.g.,
SIVmac239( nef)-infected RMs) and among CD8  cells,
suggesting that the primary inciting stimulus for this re-
sponse is infection-mediated immune stimulation, rather
than a homeostatic response to T cell depletion. More-
over, given that high proliferative/high turnover state was
strongly manifest in the CD4  memory compartment of
SIVmac155T3-infected RMs, which almost completely
lacked a naive CD4  T cell compartment from weeks 2–10
or longer, the increased proliferation/turnover would ap-
pear to primarily involve preestablished CD4  memory T
cells, rather than recent naive to memory converts re-
sponding to antigen for the first time. In WT SIVmac239-
infected normal progressors, and in all SIVmac239( nef)-
and SIVmac155T3-infected RMs, the increased CD4 
memory T cell proliferative rates were maintained through-
out the entire 200 d of observation. However, although
WT SIVmac239-infected rapid progressors initiated the
memory T cell proliferative response with similar kinetics,
the CD4  component uniformly failed in these animals by
day 42 after infection (P   0.0001), and CD4  memory
T cell proliferative and turnover rates returned to or ap-
proached baseline values thereafter.Picker et al. 1311
The potential impact of this CD4  memory proliferative
collapse on peripheral tissues was revealed by another series
of observations. First, as explained in Results, both the ki-
netics of BrdU labeling of blood, lymph node, and BAL T
cells, and the pattern of Ki-67 expression by these labeled
cells, firmly establish that the pulmonary tissue–air interface
of SIV-infected normal progressors is constantly being
seeded by recently divided CD4  memory T cells, origi-
nating elsewhere (likely organized lymphoid tissues). Thus,
SIV infection increases CD4  memory T cell proliferation
in peripheral lymphoid tissues, producing progeny that di-
rectly disperse to extralymphoid effector sites. Because
there is both a paucity of Ki-67high T cells and minimal im-
mediate BrdU uptake by T cells in BALs, these cells do not
appear to further proliferate in these sites, but given the
rapid decline in BrdU labeling observed in our BAL sam-
ples (Fig. 7), likely die in situ, only to be continuously re-
placed by subsequent rounds of proliferation/migration.
Second, in other studies, we have used cytokine flow cy-
tometry and pan-SIV genome consecutive peptide mixes,
as well as RhCMV whole viral preps and selected RCMV
peptide mixes, to investigate the antigen specificity of the
post-SIV infection memory T cell proliferative response.
These analyses revealed that total SIV-specific responses
could account, at most, for 25% of the postinfection mem-
ory T cell proliferating (Ki-67  or immediate BrdU ) sub-
set (usually much less), and that responses to RhCMV were
invariably a component of the increased memory T cell
proliferative activity (unpublished data). Moreover, we
have recently found that provision of IL-15 to uninfected
RMs elicits a burst of CD4  and CD8  memory T cell
production and tissue homing similar to that observed in
SIV infection (unpublished data), and published reports
suggest that IL-7 has related properties (50–53), indicating
the potential of infection-induced pro-proliferative cyto-
kines to broadly stimulate CD4  and CD8  memory T cell
proliferation. Taken together, these data suggest that the
postinfection CD4  memory T cell proliferative response is
composed of diverse antigen specificities, including cells re-
sponsive to opportunistic pathogens.
With this background, a potential linkage between the
CD4  memory T cell proliferative response and rapid pro-
gression in CCR5-tropic SIV infection can be proposed.
We posit that in the setting of profound CD4  memory T
cell depletion, the increased production and tissue emigra-
tion of broadly reactive CD4  memory T cells are essential
for maintenance of immune competence. These cells are
short-lived, and with failure of the CD4  memory T cell
proliferative response, their continuous flow into potential
effector sites (especially environmental interface tissues such
as the lung, gastrointestinal tract mucosa, and skin) ceases,
depriving these sites of critically needed immunologic
function. In SIVmac239-infected RMs destined for normal
progression, even those with profound tissue CD4  T cell
depletion, we demonstrated that BAL CD4  T cells express
either or both CCR5 and Ki-67, consistent with their re-
cent production and migration (the new CCR5  effector
cell influx explaining the apparent paradox of why, in most
CCR5-tropic SIV infections, the majority of CD4  T cells
in markedly depleted effector sites still retain CCR5 ex-
pression). In sharp contrast, the CD4  T cells remaining in
the BALs of rapid progressors after day 42 after infection
(e.g., after the failure of the postinfection proliferative re-
sponse) were almost all CCR5  and Ki-67 , consistent
with a lack of influx of newly produced cells. Although the
critical functions provided by these newly produced, short-
lived, tissue-homing CD4  memory T cells remain specu-
lative, the strong mutual correlation between CD4  mem-
ory T cell production (e.g., proliferative failure), BAL
CD4  T cell phenotype, and clinical outcome strongly sug-
gests that the dual loss of preexistent CD4  memory T cells
in tissue and the ability to produce replacements result in
local immunodeficiency, setting up such animals for the
stochastic occurrence of opportunistic infection.
If loss of tissue-homing, activated CD4  memory T cells
does, as we suggest, play a crucial role in the pathogenesis
of rapid progression, then it follows that normal progressors
avoid early pathogenesis by the sustained production of
such cells. It is important to note that this CD4  memory T
cell production response is likely a major component of the
persistent immune hyperactivation state that has been asso-
ciated with chronic pathogenesis in HIV infection (3–5).
Thus, persistent immune activation might not be solely
pathologic. At least for the CD4  T cell lineage in the SIV-
RM model, its memory T cell production component ap-
pears to be critical for the maintenance of immune compe-
tence in the face of tissue memory T cell depletion. This
benefit might very well be “accidental,” arising from a
generalized response to viral infection that evolved for pur-
poses other than offsetting massive CD4  T cell destruc-
tion. Moreover, continuous high level production of short-
lived CD4  memory T cells would likely represent only a
temporary solution to the ongoing destructive effects of vi-
ral replication, and may introduce or exacerbate pathologi-
cal processes as well. For example, CD4  memory T cell
hyperproliferation clearly provides a continuous source of
new target cells for CCR5-tropic SIV (Fig. 2 A), likely fa-
cilitating viral replication and evolution. In addition, the
long-term maintenance of markedly increased CD4 and/or
CD8  memory T cell production/turnover may ultimately
result in cellular hypofunctionality and/or deleterious alter-
ations in memory differentiation and repertoire, factors that
would contribute to the development of immunodefi-
ciency in chronic infection.
The strong coreceptor dependence of CD4  T depletion
in acute SIV infection strongly suggests that viral infection,
either directly or via CTL-mediated killing, mediates this
process. The observation that SIVmac155T3-infected RMs
experience a similar elevation of memory T cell activation/
turnover as SIVmac239-infected animals, yet preserve BAL
CD4  memory T cell populations, suggests that indirect kill-
ing via activation-induced apoptosis does not play a major
role in the early loss of CD4  memory T cells in SIVmac239
infections. The CD4  memory T cell proliferative failure in
SIVmac239-infected rapid progressors may have a similar
origin. Sustained high viral replication might directly destroyDeterminants of Rapid Progression in SIV Infection 1312
proliferating CD4  CCR5  memory T cells and/or their
immediate precursors or progeny, leaving their CD8  coun-
terparts intact. It is noteworthy, however, that (a) the CD4 
memory T cell proliferative response does initiate in rapid
progressors in the face of very high viral replication; (b) not
all the proliferating/high turnover cells are CCR5 ; (c) the
fate of these cells in acute infection, as determined by BrdU
labeling decay, appears to be no different than the fate of
similarly labeled cells in normal progressors (Fig. 6 B); and
(d) the collapse of CD4  memory T cell proliferation in
rapid progression is not total, as a relatively long-lived CD4 
memory proliferative component remains intact (Figs. 5 and
6 C). These observations suggest mechanisms other than
overwhelming, direct, virus-mediated destruction might also
be operative; perhaps a concomitant destruction of support-
ing lymphoid microenvironments (e.g., IL-15– or IL-7–
producing macrophages/stromal cells). Given the relative
preservation of the CD8  memory and long-lived CD4 
memory T cell proliferative compartments in rapid progres-
sors, this mechanism would entail an increased sensitivity of
the short-lived, tissue-homing CD4  memory compartment
to the putative microenvironmental defect (4). The relative
contribution of these mechanisms and whether the operative
mechanisms are reversible with viral suppression or immu-
notherapy (e.g., provision of pro-proliferative cytokines) re-
mains to be determined in future studies.
Rapid progression is relatively uncommon in human
HIV infection (54), and thus, the applicability of these find-
ings to the pathogenesis of most human AIDS cases re-
mains uncertain. However, the immune deficiency syndrome
manifest by our rapid progressor RM is highly analogous to
human AIDS (1, 2, 55), and our data unequivocally demon-
strate that such a clinical state can be strongly associated
with the combination of profound mucosal CD4  memory
T cell depletion and loss of an apparently compensating, in-
fection-associated proliferative response. These findings per-
suasively argue that tissue CD4  memory/effector T cell
dynamics can be a key arbitrator of progressive disease. In
addition, the CD4 memory T cell depletion and hyperpro-
liferation/turnover initiated in acute infection almost cer-
tainly has a prolonged impact on immune physiology there-
after, and thus our results provide a framework for further
analysis of chronic phase T cell memory dynamics in SIV-
infected monkeys that escape rapid progression. As evidence
is accumulating that mucosal CD4  memory T cell deple-
tion and increased CD4  memory T cell proliferation and
turnover also occur in HIV infection (3, 4, 56–60), it is
highly likely that the mechanisms operating in SIV-infected
RMs will have many direct parallels in human AIDS.
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